Genghis you well may be right, but its not the way i see it, If they spend all the £77mil that likely to be a good thing! they are not stupid, it will mean that the trails have progessed. it could be that it will all go well enough on all the drug lines and then they all go wrong at the final stages, that is the risk. and its a high risk high gain game. or am i missing something
Freddie That is no way to value a company. We all know that £77m is committed to be spent on the trials over the next couple of years, if nothing were to happen in the meantime the co would be left worth less on that logic. The true value is in the IP, and atm that is unquantifiable.
By holding here we are all judging that IP is worth considerably more than the current market cap on its own, and the drawdown of the cash will enhance it to a greater degree than the cash spent. The cash pile is really of little relevance other than to give comfort that the co is funded through trials and will not require a fundraise.
Hi Bobba. I hope Reneuron consolidates its share by at least 10/1 to reduce the silly swings we have been experiencing over recent years. A bit more stability is whats needed to allow realistic movement in any direction. Hopefully upwards. I would still like to know whose been dumping though! Best wishes and good luck. Freddie
Based on a current share valuation of 3p we are worth £94.7m We have (mainly current) assets of £77m. On this basis our research to date and intellectual assets are worth under £20M. Somethings wrong somewhere. Come on you canny investors and join our club. The clocks ticking leading up to significant news releases later this year. Freddie
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.